Company news

Zhejiang Huahai Pharmaceutical Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Announcement on Disclosure of the 2025 Annual Report by the Holding Subsidiary, Changxing Pharmaceutical Co., Ltd.

April 28, 2026

Announcement on the Return of Raised Funds

April 24, 2026

Announcement on Holding Open Day Activities for Investor

April 21, 2026

Announcement on Resolutions of the 10th Extraordinary Meeting of the 9th Board of Directors

April 17, 2026

Earnings Preannouncement for Q1 2026

April 14, 2026

Indicative Announcement on Expected Trigger of Downward Revision for the Conversion Price of ""Huahai Convertible Bonds"

April 10, 2026

Announcement on Conversion Result of Convertible Corporate Bonds and Share Changes

April 1, 2026

Announcement on Resolutions of the 9th Extraordinary Meeting of the 9th Board of Directors

March 27, 2026

Announcement on Resolutions of the 8th Extraordinary Meeting of the 9th Board of Directors

March 20, 2026

Announcement on Maturity of Partial Idle Raised Funds Used for Cash Management

March 19, 2026

Announcement on Subsidiary HB0025 Injection Initiating Endometrial Cancer Phase III Clinical Trial

March 18, 2026

Announcement on Obtaining the U.S. FDA Approval for the Product Gabapentin Capsules

March 10, 2026

Announcement on Obtaining Drug Registration Certificate by Subsidiary

March 9, 2026

Announcement on Progress in Legal Proceedings Involving the Company and Its Subsidiaries

February 27, 2026

Announcement on Obtaining the Notice on Approval of Drug Supplement Application

February 3, 2026

Announcement on Expected Decrease in Performance for 2025

January 26, 2026

On-Site Inspection Report of Zheshang Securities Co., Ltd. on Continuous Supervision over ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. in 2025

January 5, 2026

Announcement on Release of Pledge of Partial Equity of Shareholder

December 31, 2025

Announcement on Optional Repurchase Results of "Huahai Convertible Bonds"

December 30, 2025

Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial

December 26, 2025

Announcement on Progress in Drug Clinical Trials by Subsidiary

November 19, 2025

Announcement on Convening the Q3 2025 Performance Briefing

November 10, 2025

Announcement on the Subsidiary Passing On-site Inspection by FDA

November 6, 2025

Announcement on Not Revising Downward the Conversion Price of ""HUAHAI Convertible Bonds"

November 5, 2025

Report for Q3 2025

October 30, 2025

Announcement on Products Being Prospective Winners in the 11th National Centralized Drug Procurement

October 28, 2025

← Newer news releases